United Kingdom Pain Management Drugs Market Size, Share, Opportunities, And Trends By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Acetaminophen, Opioid (Strong Opioid, Weak Opioid), Antidepressants, Anticonvulsant Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Indication (Cancer, Rheumatoid Arthritis, Chronic Back Pain, Post-Operative Pain, Others), And By State - Forecasts From 2025 To 2030 - Forecasts From 2025 To 2030

United Kingdom Pain Management Drugs Market Size:

The United Kingdom pain management drugs market is expected to grow at a CAGR of 3.63% from 2025 to 2030.

The demand for these drugs in the country is poised to grow in the forecast period as surgical procedures here are considered to be the most important treatment offered by the National Health Service in secondary care within the country. This is further supported by the growing number of surgeons which further shows the growth of the healthcare sector of the country.

The growing prevalence of cancer and other chronic diseases is further expected to positively impact the growth of the market during the next five years. Additionally, with the growing number of geriatric people, aged 65 years and above, the number of age-associated diseases such as back pain, arthritis, and osteoporosis is growing and hence the market for these drugs will also continue to soar due to the requirement for drugs used in the pain management of these diseases.

According to Age UK, England witnessed a total of 22 million people who aged over 50 which was equivalent to two in five of the total population. Thus, the UK population of people aged 50+ in England was projected to increase by 19.3% between 2024 and 2044 (an increase of 4.3 million people).

Furthermore, the rising health expenditure of the country is further providing an opportunity for the market growth in the forecast period. According to the Office for National Statistics-UK Health Accounts, the health expenditure in the United Kingdom increased by 6.5% in nominal terms between 2023 and 2024 and valued approximately 317 billion euros in 2024. 

United Kingdom Pain Management Drug Market Segmentation

• By Drug Type
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Acetaminophen
  • Opioid
    • Strong Opioid
    • Weak Opioid
  • Antidepressants
  • Anticonvulsant Drugs
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Indication
  • Cancer
  • Rheumatoid Arthritis
  • Chronic Back Pain
  • Post-Operative Pain
  • Others
• By State
  • England
  • Scotland
  • Wales
  • Northern Ireland

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

5.1. Introduction

5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.3. Corticosteroids

5.4. Acetaminophen

5.5. Opioid

5.5.1. Strong Opioid

5.5.2. Weak Opioid

5.6. Antidepressants

5.7. Anticonvulsant Drugs

5.8. Others

6. UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Hospital Pharmacies

6.3. Retail Pharmacies 

6.4. Online Pharmacies

7. UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET BY INDICATION

7.1. Introduction

7.2. Cancer

7.3. Rheumatoid Arthritis

7.4. Chronic Back Pain

7.5. Post-Operative Pain

7.6. Others

8. UNITED KINGDOM PAIN MANAGEMENT DRUGS MARKET BY STATE

8.1. Introduction

8.2. England

8.2.1. By Drug Type

8.2.2. By Distribution Channel

8.2.3. By Indication

8.3. Scotland

8.3.1. By Drug Type

8.3.2. By Distribution Channel

8.3.3. By Indication

8.4. Wales

8.4.1. By Drug Type

8.4.2. By Distribution Channel

8.4.3. By Indication

8.5. Northern Ireland

8.5.1. By Drug Type

8.5.2. By Distribution Channel

8.5.3. By Indication

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. GlaxoSmirthKline plc (GSK)

10.2. Novartis Pharmaceuticals Corporation (Novartis AG)

10.3. Pfizer Inc.

10.4. Abbott Laboratories

10.5. Medtronic

10.6. Sanofi

10.7. Reckitt Benckiser Group plc

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

GlaxoSmirthKline plc (GSK)

Novartis Pharmaceuticals Corporation (Novartis AG)

Pfizer Inc.

Abbott Laboratories

Medtronic

Sanofi

Reckitt Benckiser Group plc